VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$99.9M
This Quarter Return
+21.8%
1 Year Return
+37.46%
3 Year Return
+659.14%
5 Year Return
–
10 Year Return
–
AUM
$116M
AUM Growth
+$116M
(+26%)
Cap. Flow
+$16.9M
Cap. Flow
% of AUM
14.61%
Top 10 Holdings %
Top 10 Hldgs %
86.64%
Holding
50
New
32
Increased
4
Reduced
2
Closed
4
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$6.7M |
| 2 |
Protara Therapeutics
TARA
|
$5.31M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$2.32M |
| 4 |
Replimune Group
REPL
|
$2.2M |
| 5 |
Tourmaline Bio
TRML
|
$1.88M |
Top Sells
| 1 |
Praxis Precision Medicines
PRAX
|
$3.9M |
| 2 |
scPharmaceuticals
SCPH
|
$2.36M |
| 3 |
TELA Bio
TELA
|
$1.89M |
| 4 |
OPTN
OptiNose
OPTN
|
$1.44M |
| 5 |
Context Therapeutics
CNTX
|
$1.26M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alector
ALEC
$238M
| $104K | 0.09% |
+55,000
| New | +$104K |
|
|
27
Context Therapeutics
CNTX
$75.4M
| $94.5K | 0.08% |
90,000
-1,200,323
| -93% | -$1.26M |
|
28
Terns Pharmaceuticals
TERN
$609M
| $94.2K | 0.08% |
+17,000
| New | +$94.2K |
|
29
Ventyx Biosciences
VTYX
$171M
| $76.7K | 0.07% |
+35,000
| New | +$76.7K |
|
30
Enanta Pharmaceuticals
ENTA
$180M
| $74.8K | 0.06% |
+13,000
| New | +$74.8K |
|
31
Larimar Therapeutics
LRMR
$310M
| $69.7K | 0.06% |
+18,000
| New | +$69.7K |
|
32
Gossamer Bio
GOSS
$562M
| $67.8K | 0.06% |
+75,000
| New | +$67.8K |
|
33
Aclaris Therapeutics
ACRS
$209M
| $67K | 0.06% |
+27,000
| New | +$67K |
|
34
Ovid Therapeutics
OVID
$91M
| $65.4K | 0.06% |
+70,000
| New | +$65.4K |
|
35
4D Molecular Therapeutics
FDMT
$288M
| $55.7K | 0.05% |
+10,000
| New | +$55.7K |
|
36
Sutro Biopharma
STRO
$72.7M
| $55.2K | 0.05% |
+30,000
| New | +$55.2K |
|
37
PMV Pharmaceuticals
PMVP
$74.2M
| $52.9K | 0.05% |
+35,000
| New | +$52.9K |
|
38
FibroGen
FGEN
$47.8M
| $42.4K | 0.04% |
+80,000
| New | +$42.4K |
|
39
CytomX Therapeutics
CTMX
$336M
| $36.1K | 0.03% |
+35,000
| New | +$36.1K |
|
|
KRON
40
DELISTED
Kronos Bio
KRON
| $33.3K | 0.03% |
+35,000
| New | +$33.3K |
|
41
Karyopharm Therapeutics
KPTI
$61.7M
| $27.1K | 0.02% |
+40,000
| New | +$27.1K |
|
42
Bolt Biotherapeutics
BOLT
$9.85M
| $26.8K | 0.02% |
+50,000
| New | +$26.8K |
|
|
ELEV
43
DELISTED
Elevation Oncology
ELEV
| $25.3K | 0.02% |
+45,000
| New | +$25.3K |
|
44
Cocrystal Pharma
COCP
$15.4M
| $20.2K | 0.02% |
+10,000
| New | +$20.2K |
|
45
NextCure
NXTC
$13.5M
| $19.3K | 0.02% |
+25,000
| New | +$19.3K |
|
|
OPTN
46
DELISTED
OptiNose
OPTN
| – | – |
-2,146,608
| Closed | -$1.44M |
|
|
47
scPharmaceuticals
SCPH
$295M
| – | – |
-517,668
| Closed | -$2.36M |
|
|
48
TELA Bio
TELA
$70.5M
| – | – |
-747,410
| Closed | -$1.89M |
|
49
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|
50
Skye Bioscience
SKYE
$108M
| – | – |
-211,071
| Closed | -$825K |
|